IN191496B - - Google Patents

Info

Publication number
IN191496B
IN191496B IN1036DE1999A IN191496B IN 191496 B IN191496 B IN 191496B IN 1036DE1999 A IN1036DE1999 A IN 1036DE1999A IN 191496 B IN191496 B IN 191496B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Yatendra Kumar
Rakesh Kumar Arora
Kaptan Singh
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Priority to IN1036DE1999 priority Critical patent/IN191496B/en
Priority to PCT/IB2000/001024 priority patent/WO2001009143A1/en
Priority to US10/048,354 priority patent/US6602999B1/en
Priority to AU58391/00A priority patent/AU5839100A/en
Priority to BR0012865-1A priority patent/BR0012865A/pt
Priority to EP00944159A priority patent/EP1204667A4/en
Priority to JP2001513950A priority patent/JP2003506329A/ja
Priority to CN00812246A priority patent/CN1371381A/zh
Priority to ZA200200692A priority patent/ZA200200692B/en
Publication of IN191496B publication Critical patent/IN191496B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN1036DE1999 1999-07-30 1999-07-30 IN191496B (OSRAM)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IN1036DE1999 IN191496B (OSRAM) 1999-07-30 1999-07-30
PCT/IB2000/001024 WO2001009143A1 (en) 1999-07-30 2000-07-24 An improved amorphous form of cefpodoxime proxetil
US10/048,354 US6602999B1 (en) 1999-07-30 2000-07-24 Amorphous form of cefpodoxime proxetil
AU58391/00A AU5839100A (en) 1999-07-30 2000-07-24 An improved amorphous form of cefpodoxime proxetil
BR0012865-1A BR0012865A (pt) 1999-07-30 2000-07-24 Uma forma amorfa aperfeiçoada da proxetil cefpodoxima
EP00944159A EP1204667A4 (en) 1999-07-30 2000-07-24 AN IMPROVED AMORPHE FORM OF CEFPODOXIM PROXETIL
JP2001513950A JP2003506329A (ja) 1999-07-30 2000-07-24 セフポドキシメプロキセチルの改良アモルファス形態
CN00812246A CN1371381A (zh) 1999-07-30 2000-07-24 改进的无定形头孢泊肟酯
ZA200200692A ZA200200692B (en) 1999-07-30 2002-01-25 An improved amorphous form of cefpodoxime proxetil.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1036DE1999 IN191496B (OSRAM) 1999-07-30 1999-07-30

Publications (1)

Publication Number Publication Date
IN191496B true IN191496B (OSRAM) 2003-12-06

Family

ID=11092065

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1036DE1999 IN191496B (OSRAM) 1999-07-30 1999-07-30

Country Status (9)

Country Link
US (1) US6602999B1 (OSRAM)
EP (1) EP1204667A4 (OSRAM)
JP (1) JP2003506329A (OSRAM)
CN (1) CN1371381A (OSRAM)
AU (1) AU5839100A (OSRAM)
BR (1) BR0012865A (OSRAM)
IN (1) IN191496B (OSRAM)
WO (1) WO2001009143A1 (OSRAM)
ZA (1) ZA200200692B (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT408226B (de) * 1999-05-05 2001-09-25 Biochemie Gmbh Kristalliner 7-(2-(2-formylaminothiazol-4-yl)-2
WO2002068429A1 (en) * 2001-02-27 2002-09-06 Ranbaxy Laboratories Limited Process for the preparation of cefpodoxime proxetil
EP1716114A1 (en) * 2004-10-18 2006-11-02 Teva Pharmaceutical Industries Ltd. Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent
EA200702518A1 (ru) * 2005-05-16 2008-04-28 Элан Фарма Интернэшнл Лимитед Композиции на основе наночастиц и с контролируемым высвобождением, включающие цефалоспорин
KR100840132B1 (ko) * 2007-04-17 2008-06-23 재단법인서울대학교산학협력재단 포화 액체 이산화탄소를 사용한 세포독심 프록세틸의 건조
CA2884640A1 (en) * 2012-09-11 2014-03-20 Dr. Reddy's Laboratories Limited Enzalutamide polymorphic forms and its preparation
ES2892029T3 (es) * 2012-09-11 2022-02-01 Medivation Prostate Therapeutics Llc Formulaciones de enzalutamida
WO2016144918A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
WO2017046756A1 (en) * 2015-09-18 2017-03-23 Lupin Limited Proxetil and axetil esters of cefixime
JP2019520321A (ja) * 2016-05-09 2019-07-18 アナコール ファーマシューティカルズ，インコーポレイテッド フリー体のクリサボロールの結晶形ならびにそれらの調製方法および使用
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
US10118932B2 (en) * 2016-06-16 2018-11-06 Xenon Pharmaceuticals Inc. Solid state forms of spiro-oxindole compounds
US10717715B2 (en) * 2016-09-06 2020-07-21 Indena S.P.A. Solid forms of ingenol 3-(3,5-diethylisoxazole-4-carboxylate) and method for preparing the same
SG11201901457TA (en) 2016-09-07 2019-03-28 Atea Pharmaceuticals Inc 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
IL295609B2 (en) * 2017-02-01 2023-11-01 Atea Pharmaceuticals Inc Nucleotide hemisulfate salt for the treatment of hepatitis C virus
DK3601265T3 (da) * 2017-03-30 2023-09-18 Merck Patent Gmbh Fast form af (s)-[2-chlor-4-fluor-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
SMT202300327T1 (it) * 2017-11-22 2023-11-13 Agios Pharmaceuticals Inc Forme cristalline di n-(4-(4-(ciclopropilmetil) piperazin-1-carbonil)fenil)chinolina-8-solfonammide
CA3096984A1 (en) * 2018-04-05 2019-10-10 Sumitomo Dainippon Pharma Oncology, Inc. Axl kinase inhibitors and use of the same
CN112351799A (zh) 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
CN110251467A (zh) * 2019-06-26 2019-09-20 北京济美堂医药研究有限公司 一种无定形态头孢妥仑匹酯组合物的制备方法
CN110437259B (zh) * 2019-08-14 2021-12-07 中国药科大学 头孢泊肟酯柚皮素共无定形物及其制备方法
JP2022551439A (ja) * 2019-10-04 2022-12-09 スミトモ ファーマ オンコロジー， インコーポレイテッド Ａｘｌ阻害薬製剤
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
JP2024525164A (ja) 2021-06-17 2024-07-10 アテア ファーマシューティカルズ， インコーポレイテッド 有利な抗ｈｃｖ併用療法
EP4530380A1 (en) 2022-05-23 2025-04-02 Nagoya Institute Of Technology Method for continuously producing biodegradable fiber material containing inorganic filler particles using wet spinning, and cotton-like bone regeneration material produced with said method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223153A (en) 1979-02-09 1980-09-16 Eli Lilly And Company Crystalline forms of N-2-(6-methoxy)benzothiazolyl N'-phenyl urea
IT1165253B (it) 1979-07-12 1987-04-22 Blasinachim Spa Procedimento di fabbricazione di acido chenodesossicolico cristallino puro
US4486425A (en) 1980-09-30 1984-12-04 Sankyo Company Limited 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates
YU44680B (en) 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
DK0531875T3 (da) * 1991-09-07 2004-06-21 Aventis Pharma Gmbh Diastereomer af 3-cephem-4-carboxylsyre-1-(-isopropoxycarbonyloxy)-ethylester og fremgangsmåde til dens fremstilling
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
AT413383B (de) * 1998-01-09 2006-02-15 Sandoz Ag Verfahren zur isolierung eines diastereoisomerengemisches von cefpodoxim proxetil
KR100342943B1 (ko) 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물

Also Published As

Publication number Publication date
JP2003506329A (ja) 2003-02-18
ZA200200692B (en) 2003-05-28
WO2001009143A1 (en) 2001-02-08
AU5839100A (en) 2001-02-19
EP1204667A1 (en) 2002-05-15
US6602999B1 (en) 2003-08-05
EP1204667A4 (en) 2002-10-30
BR0012865A (pt) 2002-07-09
CN1371381A (zh) 2002-09-25

Similar Documents

Publication Publication Date Title
BE2013C001I2 (OSRAM)
BE2012C036I2 (OSRAM)
BE2008C046I2 (OSRAM)
BE1025464I2 (OSRAM)
BE2010C011I2 (OSRAM)
BRPI0017527B8 (OSRAM)
JP2002507757A5 (OSRAM)
JP2002502043A5 (OSRAM)
JP2002521141A5 (OSRAM)
BE2008C047I2 (OSRAM)
BE2011C004I2 (OSRAM)
JP2000286458A5 (OSRAM)
IN191496B (OSRAM)
JP2002525223A5 (OSRAM)
JP2002528905A5 (OSRAM)
JP2002526310A5 (OSRAM)
IN187487B (OSRAM)
IN187119B (OSRAM)
BRPI9917761A2 (OSRAM)
BRPI0303609A (OSRAM)
FR2776171A3 (OSRAM)
IN186577B (OSRAM)
AU2000269752A8 (OSRAM)
BY5430C1 (OSRAM)
CN3098238S (OSRAM)